|
Figure 1.1: Phases of the Drug
Development Process That Are Impacted by Biomarkers
Figure 1.2: Effective Profitability
of Approved and Released Pharmaceuticals
Figure 1.3: Value Proposition
of Biomarkers Throughout the Therapeutic Development and Application
Phases
Figure 1.4: Reasons Cited for
Compound Failure
Figure 1.5: The Biomarker Research
and Development Process
Figure 2.1: Linkage of a Basic
Systems Biology Research Cycle with Drug Discovery and Treatment
Figure 2.2: How Technologies
Can Better Connect Discovery and Clinical Research
Table 1.1: Biomarker/Surrogate
Endpoints That Have Aided Drug Development
Table 1.2: Classification of
Biomarkers as Described by the FDA
Table 2.1: Comparative Throughput
of Biomarker Technologies
Table 2.2: Gene Expression as
a Prognostic Tool in Breast Cancer
Table 2.3: Genes for Early-Onset
Alzheimer’s Disease
Table 2.4: Genes for Late-Onset
Alzheimer’s Disease
Table 2.5: Comparison of Proteomic
Technologies Used for Biomarker Discovery
Table 2.6: Comparison of Advantages
and Disadvantages of Selected Molecular Imaging Technologies
Table 4.1: Pharmacological MRI
Studies Involving Psychiatric and Neurological Conditions
Table 5.1: Selected Pharmaceutical
Company Partnerships
| 
